Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 0.85 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.85 |
| ▸ | ITGB1 | P05556 | 17/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12955399 | 1.00 | ITGA4 (0.85) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13376853 | 0.94 | ITGA4 (0.80) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13656581 | 0.94 | ITGA4 (0.85) | ITGA4ITGB7ITGB1 | |
| SCHEMBL3005744 | 0.92 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL29082839 | 0.92 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13656586 | 0.92 | ITGA4 (0.79) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13656576 | 0.91 | ITGA4 (0.86) | ITGA4ITGB7ITGB1 | |
| SCHEMBL6015064 | 0.90 | ITGA4 (0.69) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13819338 | 0.90 | ITGA4 (0.69) | ITGA4ITGB7ITGB1 | |
| SCHEMBL13376867 | 0.90 | ITGA4 (0.76) | ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-20250206825-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | OSAKA UNIVERSITY (JP) | 2025-06-26 | — | — | US | claimed |
| EP-4491196-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | OSAKA UNIVERSITY (JP) | 2025-01-15 | — | — | EP | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2023171789-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | 国立大学法人大阪大学 | 2023-09-14 | — | — | WO | claimed |
| WO-2023147555-A2 | METHODS OF TREATING PAIN | ENDOSOME THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | claimed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-7737274-B2 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof | AJINOMOTO CO., INC. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20100137593-A1 | CRYSTALS OF PHENYLALANINE DERIVATIVES AND PRODUCTION METHODS THEREOF | AJINOMOTO CO., INC (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137593-A1 | CRYSTALS OF PHENYLALANINE DERIVATIVES AND PRODUCTION METHODS THEREOF | AJINOMOTO CO., INC (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2103601-A1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | Ajinomoto Co., Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137593-A1 | CRYSTALS OF PHENYLALANINE DERIVATIVES AND PRODUCTION METHODS THEREOF | PAH, FARSA, TYR | ITGA4 4848/4885ITGB7 4827/4885ITGB1 4788/4885 |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | PAH, DDC, AADAT | ITGA4 4848/4885ITGB7 4382/4885ITGB1 4840/4885 |
| US-20250206825-A1 | COMPOSITION FOR PREVENTING OR TREATING MYOCARDITIS, COMPRISING VLA-4 INHIBITOR | FABP3, TNNI3, MYLK2 | ITGA4 8/4885ITGB7 210/4885ITGB1 51/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | ITGA4 4051/4885ITGB7 1462/4885ITGB1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.